Eton Pharmaceuticals (ETON)
NASDAQ:ETON
Want to see ETON full AI Analyst Report?
ETON Stock Chart & Stats
$25.04
-$0.03(-0.25%)
At close: 4:00 PM EST
$25.04
-$0.03(-0.25%)
Day’s Range― - ―
52-Week Range$13.09 - $35.66
Previous CloseN/A
Volume127.06K
Average Volume (3M)385.86K
Market Cap
$889.70M
Enterprise Value$889.96M
Total Cash (Recent Filing)$19.66M
Total Debt (Recent Filing)$12.25M
Price to Earnings (P/E)―
Beta0.81
Next Earnings
Aug 06, 2026EPS Estimate
0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.05
Shares Outstanding27,392,359
10 Day Avg. Volume320,335
30 Day Avg. Volume385,864
Financial Highlights & Ratios
PEG Ratio-7.42
Price to Book (P/B)17.40
Price to Sales (P/S)5.69
P/FCF Ratio44.65
Enterprise Value/Market Cap1.00
Enterprise Value/Revenue10.24
Enterprise Value/Gross Profit18.69
Enterprise Value/Ebitda163.18
Forecast
1Y Price Target
$48.50Price Target Upside93.69% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)0.8
Revenue Forecast (FY)$113.39M
Bulls Say, Bears Say
Bulls Say
Revenue Growth & Commercial MomentumSustained, high‑single to double‑digit revenue growth driven by new launches (DESMODA, HEMANGEOL) and stronger core sales signals scalable commercial execution. Durable revenue expansion supports reinvestment, better leverage of fixed costs, and underpins multi‑year growth targets.
Margin Expansion And Improving Profitability TrajectoryRising gross margins and explicit multi‑year EBITDA targets indicate durable operating leverage from specialty/orphan product mix. Higher margins from launches and anticipated product mix shift can sustainably boost cash flow conversion and fund growth without proportional SG&A increases.
Improving Balance Sheet And Financing FlexibilityMaterial debt reduction plus better credit terms lower interest cost and debt service risk, increasing financial optionality for M&A or working capital. Improved capitalization reduces refinancing pressure and supports longer‑term commercialization and R&D investments.
Bears Say
Ongoing GAAP Losses And Negative ReturnsDespite EBITDA progress, persistent GAAP losses and negative ROE indicate the company has not yet converted scale into consistent GAAP profitability. This limits retained earnings, constrains capital allocation flexibility, and means results remain sensitive to execution misses.
HEMANGEOL Reimbursement And Mix UncertaintyA large share of usage potentially covered by assistance/government programs creates structural uncertainty in realized revenue per patient and margins. Persistent adverse payer mix could permanently limit the product's revenue contribution and jeopardize margin guidance.
Cash Flow Variability And Modest Near‑term LiquidityPositive free cash flow is encouraging, but recent step‑down in operating cash and modest post‑acquisition cash leave limited near‑term cushion. Variable cash conversion and acquisition spend increase dependence on execution to sustain investment and debt servicing.
Eton Pharmaceuticals News
ETON FAQ
What was Eton Pharmaceuticals’s price range in the past 12 months?
Eton Pharmaceuticals lowest stock price was $13.09 and its highest was $35.66 in the past 12 months.
What is Eton Pharmaceuticals’s market cap?
Eton Pharmaceuticals’s market cap is $889.70M.
When is Eton Pharmaceuticals’s upcoming earnings report date?
Eton Pharmaceuticals’s upcoming earnings report date is Aug 06, 2026 which is in 47 days.
How were Eton Pharmaceuticals’s earnings last quarter?
Eton Pharmaceuticals released its earnings results on May 14, 2026. The company reported $0.14 earnings per share for the quarter, beating the consensus estimate of $0.113 by $0.027.
Is Eton Pharmaceuticals overvalued?
According to Wall Street analysts Eton Pharmaceuticals’s price is currently Undervalued.
Does Eton Pharmaceuticals pay dividends?
Eton Pharmaceuticals does not currently pay dividends.
What is Eton Pharmaceuticals’s EPS estimate?
Eton Pharmaceuticals’s EPS estimate is 0.15.
How many shares outstanding does Eton Pharmaceuticals have?
Eton Pharmaceuticals has 27,392,359 shares outstanding.
What happened to Eton Pharmaceuticals’s price movement after its last earnings report?
Eton Pharmaceuticals reported an EPS of $0.14 in its last earnings report, beating expectations of $0.113. Following the earnings report the stock price went up 1.001%.
Which hedge fund is a major shareholder of Eton Pharmaceuticals?
Currently, no hedge funds are holding shares in ETON
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Eton Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$48.50 (93.69% Upside)
$48.50 (93.69% Upside)
Blogger Sentiment
Bullish
ETON Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 75.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $8.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.9%
Last 30 Days ▲ 7.0%
Last 30 Days ▲ 7.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
137.08%
12-Months-Change
Fundamentals
Return on Equity
-5.68%
Trailing 12-Months
Asset Growth
16.28%
Trailing 12-Months
Company Description
Eton Pharmaceuticals
Eton Pharmaceuticals, Inc. functions as a specialized pharmaceutical enterprise, primarily focused on the invention and market introduction of medical treatments for rare diseases. Its current product lineup features Biorphen and Rezipres, both phenylephrine injections designed to counter significant hypotension arising from vasodilation during anesthesia. The company also offers Carglumic Acid, a treatment for acute and chronic hyperammonemia linked to N-acetylglutamate Synthase deficiency. Further marketed solutions include Alkindi Sprinkle, which serves as a replacement therapy for adrenocortical insufficiency in children younger than 17; EPRONTIA, a liquid formulation of topiramate; and Alaway Preservative Free, an ophthalmic product for allergic conjunctivitis that contains no preservatives. Beyond its existing portfolio, Eton is actively developing various pipeline assets. These encompass oral suspensions of Zonisamide and Lamotrigine, both aimed at addressing partial on-set seizures, alongside a cysteine injection, a dehydrated alcohol injection, and the Zeneo hydrocortisone autoinjector. This company was established in 2017 and is headquartered in Deer Park, Illinois.
ETON Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial momentum: record product revenue (73% YoY), successful launches of DESMODA and HEMANGEOL, raised full‑year guidance (> $120M), improving adjusted EBITDA and multiple high‑value pipeline milestones (INCRELEX label study cleared, ET‑700 and Amglidia progress). Operational scalability was highlighted by relatively modest G&A growth versus revenue growth. Key risks discussed include launch execution and reimbursement uncertainty for HEMANGEOL (large portion of volume potentially near‑zero revenue), modest margin dilution from ex‑U.S. INCRELEX shipments, higher recurring FDA program fees, and near‑term cash impacts from the HEMANGEOL acquisition. On balance, the positive commercial performance, upgraded guidance, and clear pipeline catalysts outweigh the near‑term uncertainties reported.View all ETON earnings summariesETON Stock 12 Month Forecast
Average Price Target
$48.50
▲(93.69% Upside)
Technical Analysis
Ownership Overview
5.00% Insiders
6.86% Mutual Funds
37.13% Other Institutional Investors
42.97% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---